Assessing the Reporting of Adherence and Sexual Activity in a Simulated Microbicide Trial in South Africa: An Interview Mode Experiment Using a Placebo Gel
First Online: 01 October 2010 DOI:
Cite this article as: Mensch, B.S., Hewett, P.C., Abbott, S. et al. AIDS Behav (2011) 15: 407. doi:10.1007/s10461-010-9791-z Abstract
Misreporting of adherence undermines detection of an association between product use and HIV infection in microbicide trials. This study investigates whether, in a placebo trial, audio computer-assisted self-interviewing (ACASI) produces more accurate reporting of adherence and sexual behavior than a face-to-face interview (FTFI). At three South African clinics, 849 women were enrolled and instructed to use applicators filled with placebo gel; participants were randomly assigned to FTFI or ACASI. Behavioral reports were validated through two biomarkers that detect product usage and unprotected sex. For most behaviors, ACASI generated significantly higher reporting, although differences by interview mode appeared to diminish over time. ACASI participants were more likely to report having had sex without gel, but reported and tested applicators did not indicate greater honesty about gel insertion with ACASI. While comparisons of reported unprotected sex with the validated biomarker revealed more agreement with ACASI than with FTFI, differences were small.
Keywords ACASI Adherence Biomarkers Microbicides Sexual activity References
UNAIDS. Sub-Saharan Africa: AIDS epidemic update regional summary. Geneva: UNAIDS and World Health Organization; 2008.
Bongaarts J, Buettner T, Heilig G, Pelletier F. Has the HIV epidemic peaked? Popul Dev Rev. 2008;34(2):199–224.
Padian NS, Buvé A, Balkus J, Serwadda D, Cates W Jr. HIV prevention 2: biomedical interventions to prevent HIV infection: evidence, challenges, and way forward. Lancet. 2008;372(9638):585–99.
Karim QA, Karim SSA, Frohlich JA, et al. Effectiveness and safety of Tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science. 2010;329(5996):1168–74.
Feldblum PJ, Adeiga A, Bakare R, et al. SAVVY vaginal gel (C31G) for prevention of HIV infection: a randomized controlled trial in Nigeria. PLoS ONE. 2008;3(1):e1474. PMID: 18213382.
Peterson L, Nanda K, Opoku BK, et al. SAVVY (C31G) gel for prevention of HIV infection in women: a Phase 3, double-blind, randomized, placebo-controlled trial in Ghana. PLoS ONE. 2007;2(12):e1312.
Stirratt MJ, Gordon CM. Adherence to biomedical HIV prevention methods: considerations drawn from HIV treatment adherence research. Curr HIV/AIDS Rep. 2008;5:186–92.
Stone A, Jiang S. Microbicides: stopping HIV at the gate. Lancet. 2006;368(9534):431–3.
Tolley EE, Harrison PF, Goetghebeur E, et al. Adherence and its measurement in phase 2/3 microbicide trials. AIDS Behav. 2009. doi:
Trussell J, Dominik R. Will microbicide trials yield unbiased estimates of microbicide efficacy? Contraception. 2005;72(6):408–13.
Turner AN, De Kock AE, Meehan-Ritter A, et al. Many vaginal microbicide trial participants acknowledged they had misreported sensitive sexual behavior in face-to-face interviews. J Clin Epidemiol. 2009;62(7):759–65.
Skoler-Karpoff S, Ramjee G, Ahmed K, et al. Efficacy of Carraguard for prevention of HIV infection in women in South Africa: a randomised, double-blind, placebo-controlled trial. Lancet. 2008;372(9654):1977–87.
Institute of Medicine of the National Academies Committee on the Methodological Challenges in HIV Prevention Trials. Methodological challenges in biomedical HIV prevention trials. Washington, DC: Institute of Medicine, National Academies Press; 2008.
Weiss HA, Wasserheit JN, Barnabas RV, Hayes RJ, Abu-Raddad LJ. Persisting with prevention: the importance of adherence for HIV prevention. Emerg Themes Epidemiol. 2008;5:8.
van de Wijgert J, Padian N, Shiboski S, Turner C. Is audio computer-assisted self-interviewing a feasible method of surveying in Zimbabwe. Int J Epidemiol. 2000;29:885–90.
Lara D, Strickler J, Olavarrieta CD, Ellertson C. Measuring induced abortion in Mexico. Sociol Methods Res. 2004;32(4):1–30.
Hewett PC, Erulkar AC, Mensch BS. The feasibility of computer-assisted survey interviewing in Africa: experience from two rural districts in Kenya. Soc Sci Comput Rev. 2004;22(3):319–34.
Mensch BS, Hewett PC, Gregory R, Helleringer S. Sexual behavior and STI/HIV status among adolescents in rural Malawi: an evaluation of the effect of interview mode on reporting. Stud Fam Plann. 2008;39(4):321–34. PMC:2670342.
Hewett PC, Mensch BS, Erulkar AS. Consistency in the reporting of sexual behaviour by adolescent girls in Kenya: a comparison of interviewing methods. Sex Transm Infect. 2004;80(Suppl II):ii43–8.
Mensch BS, Hewett PC, Jones HE, et al. Consistency in women’s reports of sensitive behavior within an interview mode experiment, São Paulo, Brazil. Int Fam Plan Perspect. 2008;34(4):169–76. PMC: 2723120.
Potdar R, Koenig MA. Does audio-CASI improve reports of risky behavior? Evidence from a randomized field trial among young urban men in India. Stud Fam Plann. 2005;36(2):107–16.
Minnis AM, Muchini A, Shiboski S, et al. Audio computer-assisted self-interviewing in reproductive health research: reliability assessment among women in Harare, Zimbabwe. Contraception. 2007;75(1):59–65.
Le LC, Blum RW, Magnani R, Hewett PC, Do HM. A pilot of audio-computer assisted self-interview for youth reproductive health research in Vietnam. J Adolesc Health. 2006;38(6):740–7.
van der Elst EM, Okuku HS, Nakamya P, et al. Is audio computer-assisted self-interview (ACASI) useful in risk behaviour assessment of female and male sex workers, Mombasa, Kenya? PLoS ONE. 2009;4(5):e5340.
Minnis AM, Steiner MJ, Gallo MF, et al. Biomarker validation of reports of recent sexual activity: results of a randomized controlled study in Zimbabwe. Am J Epidemiol. 2009;170:918–24.
Hewett PC, Mensch BS, Ribeiro MCSdA, et al. Using sexually transmitted infection (STI) biomarkers to validate the reporting of sexual behavior within a randomized, experimental evaluation of interviewing methods. Am J Epidemiol. 2008;168(2):202–11.
Wallace A, Thorn M, Maguire RA, Sudol KM, Phillips DM. Assay for establishing whether microbicide applicators have been exposed to the vagina. Sex Transm Dis. 2004;31(8):465–8.
Wallace AR, Teitelbaum A, Wan L, et al. Determining the feasibility of utilizing the microbicide applicator compliance assay for use in clinical trials. Contraception. 2007;76:53–6.
Mauck C, Weiner DH, Ballagh S, et al. Single and multiple exposure tolerance study of cellulose sulfate gel: a phase I safety and colposcopy study. Contraception. 2001;64(6):383–91.
Mauck CK. Biomarkers of semen exposure. Sex Transm Dis. 2009;36(3, Supplement):S81–3.
Mâsse BR, Boily MC, Dimitrov D, Desai K. Efficacy dilution in randomized placebo-controlled vaginal microbicide trials. Emerg Themes Epidemiol. 2009;6:5.
Tolley EE, Severy LJ. Integrating behavioral and social science research into microbicide clincal trials: challenges and opportunities. Am J Public Health. 2006;96(1):79–83.
Nunn A, McCormack S, Crook AM, Pool R, Rutterford C, Hayes R. Microbicide development programme: design of a phase III trial to measure the efficacy of the vaginal microbicide PRO 2000/5 for HIV prevention. Trials. 2009; 10(99).
© Springer Science+Business Media, LLC 2010